Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide maintenance after allo-HSCT for high-risk T-cell acute lymphoblastic leukemia/lymphoma
ChiCTR2300069772Phase 2Not yet recruiting
- Sponsor
- Xinqiao Hospital
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in t-cell acute lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LBL) comparing Chidamide maintenance with No maintenance (observation) (2 arms). Primary endpoint: GVHD-free/relapse-free survival at 2 years. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
tucidinostat
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T-lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on ChiCTR2300069772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069772.